136 related articles for article (PubMed ID: 28667460)
1. Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.
Borella E; Poggesi I; Magni P
Clin Pharmacokinet; 2018 Apr; 57(4):505-514. PubMed ID: 28667460
[TBL] [Abstract][Full Text] [Related]
2. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
[TBL] [Abstract][Full Text] [Related]
3. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model.
Mahmood I
Drugs R D; 2020 Dec; 20(4):377-387. PubMed ID: 33150526
[TBL] [Abstract][Full Text] [Related]
4. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.
Kamal MA; Brennan BJ; Subramoney V; Lien YT; Morcos PN; Frey N; Rayner CR
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):326-36. PubMed ID: 27137141
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study.
Zhou L; Tong X; Sharma P; Xu H; Al-Huniti N; Zhou D
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):100-107. PubMed ID: 30739396
[TBL] [Abstract][Full Text] [Related]
7. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications.
Zhang Y; Zhang L; Abraham S; Apparaju S; Wu TC; Strong JM; Xiao S; Atkinson AJ; Thummel KE; Leeder JS; Lee C; Burckart GJ; Lesko LJ; Huang SM
Clin Pharmacol Ther; 2009 Mar; 85(3):305-11. PubMed ID: 19020495
[TBL] [Abstract][Full Text] [Related]
9. An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.
Johnson FK; Mudd PN; DiMino T; Vosk J; Sitaraman S; Boudes P; France N; Barlow C
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):256-61. PubMed ID: 27136905
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.
Hamrén B; Ericsson H; Samuelsson O; Karlsson MO
Br J Clin Pharmacol; 2008 Jun; 65(6):855-63. PubMed ID: 18294322
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic analysis of thrombomodulin alfa to support dosing rationale in patients with renal impairment.
Mouksassi MS; Marier JF; Bax L; Osawa Y; Tsuruta K
Clin Pharmacol Drug Dev; 2015; 4(3):210-7. PubMed ID: 27140801
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Martin P; Oliver S; Gillen M; Marbury T; Millson D
Clin Ther; 2015 Dec; 37(12):2823-36. PubMed ID: 26519231
[TBL] [Abstract][Full Text] [Related]
14. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
Chen L; Greenberg WM; Brand-Schieber E; Wangsa J; Periclou A; Ghahramani P
Drug Des Devel Ther; 2015; 9():3293-300. PubMed ID: 26150701
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives.
Ibrahim S; Honig P; Huang SM; Gillespie W; Lesko LJ; Williams RL
J Clin Pharmacol; 2000 Jan; 40(1):31-8. PubMed ID: 10631619
[TBL] [Abstract][Full Text] [Related]
16. Strength of evidence for labeled dosing recommendations in renal impairment.
Gagne JJ; Khan NF; Raj TS; Patel LR; Choudhry NK
Clin Trials; 2017 Apr; 14(2):219-221. PubMed ID: 27780884
[TBL] [Abstract][Full Text] [Related]
17. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
18. [Appropriate pharmacotherapy in patients with chronic kidney disease - new approach - ].
Hirata S
Yakugaku Zasshi; 2012; 132(4):461-70. PubMed ID: 22465923
[TBL] [Abstract][Full Text] [Related]
19. Concordance of Exposure Changes Because of Renal Impairment Between Results of Dedicated Renal Impairment Studies and Population Pharmacokinetic Predictions.
Ahmed MA; Kalaria SN; Younis IR
J Clin Pharmacol; 2021 Oct; 61(10):1324-1333. PubMed ID: 33997992
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
Sahasrabudhe V; Terra SG; Hickman A; Saur D; Shi H; O'Gorman M; Zhou Z; Cutler DL
J Clin Pharmacol; 2017 Nov; 57(11):1432-1443. PubMed ID: 28703316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]